Novacyt SA EURONEXT:ALNOV:
NOVACYT SA - EXPECTS SLIGHT INCREASE IN H2 2025 REVENUES
NOVACYT SA - EXPECTS IMPROVEMENT IN 2025 EBITDA LOSS
NOVACYT SA - COMMITS TO DOUBLE DIGIT REVENUE GROWTH YOY FROM FY26
Novacyt SA Expects Slight Increase In H2 2025 Revenues
Watch Novacyt SAS' latest callNovacyt Sas (Euronext:ALNOV) — Interim Results Presentation · Replay · Sep 26, 2024Read the transcript of Novacyt Sas (Euronext:ALNOV) — Interim Results PresentationEarlier from Novacyt SAS
- ALNOV: EBITDA loss narrowed, cash remains strong, and reproductive health drives growth
- REG - Novacyt S.A. - Notice of Results
- REG - Novacyt S.A. - Appointment of Joint Corporate Broker
- REG - Novacyt S.A. - Resolution re. Lab 21 HSE Prosecution
- REG - Novacyt S.A. - Liquidity Agreement Monthly Update & TVR
Later from Novacyt SAS
- ALNOV: Revenue up 4% to £20.0m in 2025, with strong cash and growth in Instrumentation and APAC
- REG - Novacyt S.A. - NIPT Tender Award
- Novacyt agrees to acquire Southern Cross Diagnostics
- ALNOV: Acquisition delivers immediate profitability, expanded portfolio, and direct market access
- ALNOV: Revenue up, EBITDA loss narrowed, and cash supports growth and acquisitions
Follow Novacyt SAS into a list and get an email when it puts out news.
Follow Novacyt SAS